Skip to records

Therapeutics

229Aging Biotech
100 of 229 records

ACI-7104.056

Source date not recordedAnalyse record ↗

Alpha-synuclein active immunotherapy in an active Phase 2 study for early Parkinson's disease.

Modality
adjuvanted alpha-synuclein peptide-conjugate active immunotherapy
Availability (US)
Phase 2 VacSYn study Active, not recruiting; week-100 Part 1 update reported September 23, 2026
Biomarkers
anti-alpha-synuclein antibodies; cerebrospinal-fluid antibody levels; MRI; adverse events; clinical assessments
Hallmark targeted
loss of proteostasis, protein aggregation, neuroinflammation
Kind
investigational active immunotherapy
Clinical trials
NCT06015841 — Phase 2, Active, not recruiting on November 21, 2025 registry update